Download PDFPDF

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Expensive antirheumatic drugs - final reply

    Dear Editor,

    We have read the reply from the authors to our letter. As a final remark we would like to repeat our previous statement: “From a clinician’s perspective we think that health economic analyses in RA should always be done with intimate knowledge of the patient cohort on which the calculations are based. Any projection and modelling in other settings must be carried out with great care in close collabora...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Author's reply to: Expensive antirheumatic drugs
    • Nick Bansback, Health Economist
    • Other Contributors:
      • Alan Brennan, Ola Ghatnekar

    Dear Editor

    We very much welcome the thoughts of Drs Geborek and Saxne on our recent article,[1] and agree that a scientific approach should be taken to the synthesis of evidence in decision models. Our analysis is not the last word but rather the first decision analysis of adalimumab. The contention stems from the limitations in the evidence base. In this regard, to wait for all the evidence to be collected (possibly m...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Expensive antirheumatic drugs

    Dear Editor

    The article "Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden" by Bansbeck, Brennan, and Ghatnekar [1] deals with an important subject, i.e. is it justifiable from a cost-effectiveness point of view to use tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA).

    We acknowledge that the authors have used data from...

    Show More
    Conflict of Interest:
    None declared.